PL413921A1 - Zestaw farmaceutyczny oraz zastosowanie erytropoetyny oraz inhibitora kinazy Brutona - Google Patents

Zestaw farmaceutyczny oraz zastosowanie erytropoetyny oraz inhibitora kinazy Brutona

Info

Publication number
PL413921A1
PL413921A1 PL413921A PL41392115A PL413921A1 PL 413921 A1 PL413921 A1 PL 413921A1 PL 413921 A PL413921 A PL 413921A PL 41392115 A PL41392115 A PL 41392115A PL 413921 A1 PL413921 A1 PL 413921A1
Authority
PL
Poland
Prior art keywords
erythropoietin
application
kinase inhibitor
bruton kinase
bruton
Prior art date
Application number
PL413921A
Other languages
English (en)
Other versions
PL230756B1 (pl
Inventor
Dariusz Pawlak
Anna Tankiewicz-Kwedlo
Justyna Magdalena Hermanowicz
Krystyna Pawlak
Tomasz Kamiński
Dariusz Różkiewicz
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL413921A priority Critical patent/PL230756B1/pl
Priority to PCT/IB2016/055347 priority patent/WO2017042706A1/en
Publication of PL413921A1 publication Critical patent/PL413921A1/pl
Publication of PL230756B1 publication Critical patent/PL230756B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest zestaw farmaceutyczny charakteryzujący się tym, że zawiera erytropoetynę oraz inhibitor kinazy Brutona, zarówno w tym samym lub odrębnym opakowaniu i/lub instrukcję stosowania. Dodatkowo przedmiotem zgłoszenia jest także erytropoetyna oraz inhibitor kinazy Brutona do zastosowania jako lek. Ponadto, przedmiotem zgłoszenia jest zastosowanie erytropoetyny oraz inhibitora kinazy Brutona do wytwarzania leku do terapii nowotworu.
PL413921A 2015-09-11 2015-09-11 Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu PL230756B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL413921A PL230756B1 (pl) 2015-09-11 2015-09-11 Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
PCT/IB2016/055347 WO2017042706A1 (en) 2015-09-11 2016-09-08 Pharmaceutical kit and use of erythropoietin and bruton's kinase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL413921A PL230756B1 (pl) 2015-09-11 2015-09-11 Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu

Publications (2)

Publication Number Publication Date
PL413921A1 true PL413921A1 (pl) 2017-03-13
PL230756B1 PL230756B1 (pl) 2018-12-31

Family

ID=57233782

Family Applications (1)

Application Number Title Priority Date Filing Date
PL413921A PL230756B1 (pl) 2015-09-11 2015-09-11 Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu

Country Status (2)

Country Link
PL (1) PL230756B1 (pl)
WO (1) WO2017042706A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
US20030083250A1 (en) * 2001-10-25 2003-05-01 Francis Farrell Anti-tumor chemotherapy by administration of cyclophosphamide and erythropoeitin
DK2134374T3 (en) * 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial

Also Published As

Publication number Publication date
PL230756B1 (pl) 2018-12-31
WO2017042706A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
IL253995A0 (en) Pharmaceutical formulations of proton tyrosine kinase inhibitor
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
EA201792348A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
IL261249A (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
MX378273B (es) Compuestos activos hacia bromodominios.
MX2019014041A (es) Inhibidores pirazolicos de magl.
EA202090683A3 (ru) Способы и композиции для лечения рака
HUE053449T2 (hu) Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
PT3634415T (pt) Composições oftalmológicas que compreendem brimonidina e cetotifeno para utilização no tratamento de alergias
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.